US stocks mostly hold gains, bio-techs slip

The Dow and S&P 500 remain buoyant late in the New York trading day, but the NASDAQ has sunk into the red.

A healthy drop in jobless claims earlier today continues to lift the US stock market for the most part, with the S&P 500 on track for another closing record with most of the trading day gone. With under 20 minutes to the closing bell, the Dow was up 0.49% at 16,440, while the S&P 500 gained 0.30% to 1879.4.

The NASDAQ 100 was dragged into negative territory though, as the health care and biotechnology sector slumped. Biopharmaceutical company Gilead Sciences lost more than 3%, while competitor Amgen dropped 1.4%. Bucking the trend was Sangamo Biosciences, which rocketed more than 17% on news that a genome-modifying treatment reduced the viral load  of some HIV patients in a small study.

President Obama has signed an executive order allowing the US to impose sanctions on those considered to be violating Ukraine’s sovereignty and said that ‘We intend to impose costs on Russia for this intervention’.

The Ukrainian situation no longer appears to be hindering sentiment in the financial markets, however, and the focus tomorrow is likely to be mainly on the monthly employment report from the US Bureau of Labor Statistics. Expectations are for an increase of 149,000 to be announced for non-farm payrolls for last month.

IGA, may distribute information/research produced by its respective foreign marketing partners within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.

This information/research prepared by IGA or IGA Group is intended for general circulation. It does not take into account the specific investment objectives, financial situation or particular needs of any particular person. You should take into account your specific investment objectives, financial situation or particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. In addition to the disclaimer above, the information does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. Any views and opinions expressed may be changed without an update.

See important Research Disclaimer.